🔎 Trials Near Me

Akèy › Myelom Miltip › Illinois

Etid klinik pou Myelom Miltip nan Illinois

31 etid pou Myelom Miltip ap chèche patisipan nan sit nan Illinois.

Vil nan Illinois

Tèks ofisyèl etid la (Anglè)

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

  • Illinois CancerCare-Bloomington, Bloomington
  • Illinois CancerCare-Canton, Canton
  • Illinois CancerCare-Carthage, Carthage
  • ak 13 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06948084

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

  • University of Chicago Medical Center /ID# 278863, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07409246

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  • Research Site, Chicago
  • Research Site, Park Ridge
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07391657

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  • University Of Illinois Medical Center, Chicago
  • Loyola University Medical Center, Maywood
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05552222

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  • City of Hope Chicago, Zion
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  • Northwestern University, Chicago
  • University of Chicago, Chicago
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05201781

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Rush University System for Health, Chicago
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT05789303

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Cancer Treatment Centers of America-Chicago, Chicago
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Northwestern Memorial Hospital, Chicago
  • University of Chicago Medical Center, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

  • University of Illinois at Chicago, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05344833

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  • Endeavor Health - Swedish Hospital, Chicago
  • Endeavor Health - Evanston Hospital, Evanston
  • Endeavor Health - Glenbrook Hospital Ambulatory Care Center, Glenview
  • ak 6 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06152575

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • OSF Saint Anthony's Health Center, Alton
  • Advocate Outpatient Center - Aurora, Aurora
  • Advocate Good Shepherd Hospital, Barrington
  • ak 40 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04566328

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Chicago
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  • Research Site, Chicago
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  • Loyola University Medical Center, Maywood
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07280013

Mosaic Trial for Stem Cell Transplant Recipients

  • Northwestern University Feinberg School of Medicine, Chicago
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT06960993

Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma

  • Loyola University Chicago, Maywood
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07236502

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Hope And Healing Cancer Services /ID# 268536, Hinsdale
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT05650632

Integrated Cancer Repository for Cancer Research

  • Rush-Copley Cancer Care Center, Aurora
  • Rush-Copley Healthcare Center, Yorkville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699

Personalized Autologous Transplant for Multiple Myeloma

  • University Illinois Chicago, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 15, 2026 · NCT04483206

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Saint Anthony's Health, Alton
  • Rush - Copley Medical Center, Aurora
  • Saint Joseph Medical Center, Bloomington
  • ak 41 plis
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Jun 10, 2026 · NCT05561387

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  • University of Chicago, Chicago
  • University of Illinois Medical Center at Chicago, Chicago
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT05243797

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • University of Chicago, Chicago
Ap rekriteFaz 1
Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

  • University of Chicago Medical Center, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT05862012

Hypofractionation (Radiation) Trial for Multiple Myeloma

  • The University of Chicago Comprehensive Cancer Center, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 30, 2026 · NCT06270888

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Northwestern, Chicago
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

  • Northshore University Health System, Evanston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 23, 2026 · NCT05974150

A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

  • City of Hope at Chicago, Zion
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Feb 20, 2026 · NCT07225738

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

  • University of Illinois Cancer Center, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 18, 2025 · NCT05192122

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.